THE ROLE OF HORMONAL THERAPY IN THE MANAGEMENT OF ADENOMYOSIS

Ibragimova Nodira Shovkatovna
2026 · doi:10.5281/zenodo.20708513 · W7164845023
conference-paper OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-09 ⓘ

This review analyzes hormonal therapies like LNG-IUS, progestins, GnRH agonists, and oral contraceptives for adenomyosis, finding they effectively control symptoms, reduce uterine volume, and preserve reproductive function.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-09 · read from full text ⓘ

This conference paper is a review of hormonal therapy for adenomyosis, describing the condition as estrogen-dependent and highlighting mechanisms by which hormonal treatments suppress estrogen-related proliferation and reduce inflammatory activity in adenomyotic lesions. It surveys evidence for several hormonal options—levonorgestrel-releasing intrauterine systems, progestins (including dienogest), gonadotropin-releasing hormone agonists, and combined oral contraceptives—reporting that these approaches control symptoms, reduce uterine volume, and can help preserve reproductive function. A stated caveat is that the review emphasizes the need for individualized treatment strategies based on factors such as age, symptom severity, reproductive goals, and disease extent. This paper is centrally about adenomyosis — it focuses on the role of hormonal therapy in the management of adenomyosis and summarizes mechanisms and reported efficacy of multiple hormonal modalities.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Adenomyosis is a common estrogen-dependent gynecological disorder characterized by the presence of endometrial glands and stroma within the myometrium. The disease is frequently associated with heavy menstrual bleeding, dysmenorrhea, chronic pelvic pain, infertility, and impaired quality of life. Hormonal therapy has become the cornerstone of conservative management due to its ability to suppress estrogen-dependent proliferation and reduce inflammatory activity within adenomyotic lesions. This review analyzes the role of hormonal therapy in the treatment of adenomyosis, focusing on its mechanisms of action, clinical efficacy, and therapeutic benefits. Current evidence indicates that levonorgestrel-releasing intrauterine systems (LNG-IUS), progestins such as dienogest, gonadotropin-releasing hormone (GnRH) agonists, and combined oral contraceptives effectively control symptoms, reduce uterine volume, and preserve reproductive function. Individualized treatment strategies based on patient age, symptom severity, reproductive goals, and disease extent are essential for achieving optimal outcomes.
Full text 2,480 characters · extracted from oa-doi-fallback · click to expand
Published June 15, 2026 | Version v1 Conference paper Open THE ROLE OF HORMONAL THERAPY IN THE MANAGEMENT OF ADENOMYOSIS Authors/Creators - 1. Assistant Urgench State Medical Institute, Uzbekistan Description Adenomyosis is a common estrogen-dependent gynecological disorder characterized by the presence of endometrial glands and stroma within the myometrium. The disease is frequently associated with heavy menstrual bleeding, dysmenorrhea, chronic pelvic pain, infertility, and impaired quality of life. Hormonal therapy has become the cornerstone of conservative management due to its ability to suppress estrogen-dependent proliferation and reduce inflammatory activity within adenomyotic lesions. This review analyzes the role of hormonal therapy in the treatment of adenomyosis, focusing on its mechanisms of action, clinical efficacy, and therapeutic benefits. Current evidence indicates that levonorgestrel-releasing intrauterine systems (LNG-IUS), progestins such as dienogest, gonadotropin-releasing hormone (GnRH) agonists, and combined oral contraceptives effectively control symptoms, reduce uterine volume, and preserve reproductive function. Individualized treatment strategies based on patient age, symptom severity, reproductive goals, and disease extent are essential for achieving optimal outcomes. Files Ibragimova N 253-256 XXI.pdf Files (192.9 kB) | Name | Size | Download all | |---|---|---| | md5:f89942d46055c0e75efb2621c90ac817 | 192.9 kB | Preview Download | Additional details References - 1. Chapron, C., Vannuccini, S., Santulli, P., Abrão, M. S., Carmona, F., Fraser, I. S., & Petraglia, F. (2020). Diagnosing adenomyosis: an integrated clinical and imaging approach. Human Reproduction Update, 26(3), 392–411. - 2. Ибрагимова Н.Ш. Юсупова М.А. Аденомиоз и репродуктивные исходы // Тиббиётда янги кун. 2 (88) 2026 С 181-184 (14.00.00; №22) - 3. Ibragimova N. Sh., Yusupova M. A., Ikramova X. S. Differentiated aproach to the diagnosis of adenomiosis in women of reproductive age // Jurnal: Вестник ТМА № 10 (1) 9,2024 (14.00.00; №13) - 4. Ibragimova N. Sh., Yusupova M. A. Fertility and Adenomyosis. Solved and Unresolved Problems //Jurnal: American Journal of Medicine and Medical Sciences 2025, 15(12): 4248-4253 DOI: 10.5923/j.ajmms.20251512.11(14.00.00; №2) - 5. Vannuccini, S., Luisi, S., Tosti, C., Sorbi, F., & Petraglia, F. (2018). Role of medical therapy in the management of uterine adenomyosis. Fertility and Sterility, 109(3), 398– 405.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-07-16T11:09:27.693067+00:00
License: CC0 · commercial use OK